{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:10:42Z","timestamp":1745845842396,"version":"3.37.3"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCRR M01 RR 00037"],"award-info":[{"award-number":["NCRR M01 RR 00037"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K23 CA10069-01"],"award-info":[{"award-number":["K23 CA10069-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.09.019","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T09:59:10Z","timestamp":1727863150000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer"],"prefix":"10.1016","volume":"191","author":[{"given":"John B.","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita S.","family":"Jejurikar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie M.","family":"Hitchcock-Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Gwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Reichow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushe","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Coveler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron E.","family":"Swensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L.","family":"Disis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lupe G.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2024.09.019_bb0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"51","key":"10.1016\/j.ygyno.2024.09.019_bb0010","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.019_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian Cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.ygyno.2024.09.019_bb0020","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2024.09.019_bb0025","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of Pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase 2 KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0030","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(20)30533-7","article-title":"Gemogenovatucel-T (vigil) immunotherapy as maintenance in frontline stage III\/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"21","author":"Rocconi","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.09.019_bb0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0040","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-04-4043","article-title":"Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma","volume":"65","author":"Wei","year":"2005","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2024.09.019_bb0045","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1158\/1078-0432.CCR-18-0554","article-title":"Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma","volume":"24","author":"Toker","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0050","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0055","first-page":"4766","article-title":"Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer","volume":"61","author":"Woo","year":"2001","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0060","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/2326-6066.CIR-17-0479","article-title":"Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg\/Th17 cell imbalance in epithelial ovarian Cancer","volume":"6","author":"Zhou","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"13","key":"10.1016\/j.ygyno.2024.09.019_bb0065","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-20-4594","article-title":"IFN\u03b1 augments clinical efficacy of regulatory T-cell depletion with denileukin diftitox in ovarian cancer","volume":"27","author":"Thibodeaux","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.019_bb0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.177.1.84","article-title":"IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice","volume":"177","author":"Knutson","year":"2006","journal-title":"J. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.09.019_bb0075","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.3816\/CLM.2000.s.006","article-title":"DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date","volume":"1","author":"Kuzel","year":"2000","journal-title":"Clin. Lymphoma"},{"issue":"6","key":"10.1016\/j.ygyno.2024.09.019_bb0080","first-page":"1289","article-title":"Generation of immunity to the HER-2\/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine","volume":"5","author":"Disis","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0085","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1201-1339","article-title":"Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells","volume":"7","author":"Zou","year":"2001","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2024.09.019_bb0090","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1158\/1078-0432.CCR-12-0113","article-title":"Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells","volume":"18","author":"Dang","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.019_bb0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.09.019_bb0100","doi-asserted-by":"crossref","first-page":"viii49","DOI":"10.1093\/annonc\/mdr467","article-title":"Optimal assessment of response in ovarian cancer","volume":"22 Suppl 8","author":"Eisenhauer","year":"2011","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.09.019_bb0105","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.ygyno.2024.09.019_bb0110","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1002\/cncr.31349","article-title":"Immunotherapy and the role of imaging","volume":"124","author":"Carter","year":"2018","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2024.09.019_bb0115","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.ygyno.2024.09.019_bb0120","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2016.70.1508","article-title":"Safety and activity of Varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors","volume":"35","author":"Burris","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.019_bb0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-014-0038-9","article-title":"Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities","volume":"2","author":"Kovacsovics-Bankowski","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.019_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/IGC.0000000000000845","article-title":"The association of peripheral blood regulatory T-cell concentrations with epithelial ovarian cancer: a brief report","volume":"27","author":"Cannioto","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.019_bb0135","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1007\/s13277-015-4237-x","article-title":"Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression","volume":"37","author":"Bu","year":"2016","journal-title":"Tumour Biol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.019_bb0140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","article-title":"Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients","volume":"64","author":"Landskron","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.019_bb0145","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s12032-011-0006-x","article-title":"Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection","volume":"29","author":"Chen","year":"2012","journal-title":"Med. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.09.019_bb0150","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1631\/jzus.B1600264","article-title":"Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma","volume":"17","author":"Zhang","year":"2016","journal-title":"J Zhejiang Univ Sci B"},{"issue":"7","key":"10.1016\/j.ygyno.2024.09.019_bb0155","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.4049\/jimmunol.1003251","article-title":"IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer","volume":"186","author":"Kryczek","year":"2011","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.09.019_bb0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.medj.2024.02.003","article-title":"Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis","volume":"5","author":"Knisely","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ygyno.2024.09.019_bb0165","first-page":"OF1","article-title":"Intraperitoneal Nivolumab after Debulking surgery and Hyperthermic intraperitoneal chemotherapy in advanced ovarian Cancer: a phase I study with expansion cohort","author":"Corbaux","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.019_bb0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00262-009-0750-3","article-title":"A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer","volume":"59","author":"Vlad","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.ygyno.2024.09.019_bb0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.09.019_bb0180","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.019_bb0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2017.08.001","volume":"147","author":"Thaker","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.09.019_bb0190","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/IGC.0000000000000286","article-title":"Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study","volume":"24","author":"Berek","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2024.09.019_bb0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2015.06.003","article-title":"Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAMxanti-CD3)","volume":"138","author":"Fossati","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.ygyno.2024.09.019_bb0200","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood-2022-166916","article-title":"Efficacy and safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in patients with relapsed or refractory cutaneous T-cell lymphoma: results from pivotal study 302","volume":"140","author":"Foss","year":"2022","journal-title":"Blood"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:45:24Z","timestamp":1733881524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"alternative-id":["S0090825824011454"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.09.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}